Joint Filing AgreementJoint Filing Agreement • March 20th, 2023 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated March 20, 2023 with respect to the shares of Common Stock, par value $0.00001 per share, of Protagonist Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
